Thyroid-associated ophthalmopathy: A practical guide to classification, natural history and management

Internal Medicine Journal

Volumn 34, Issue 8, 2004, Pages 482-491

  El Kaissi, S ^a   Frauman, A G ^a   Wall, J R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoantibodies; Autoimmunity; Graves' disease; Ophthalmopathy; Orbit

Indexed keywords

ANTIBODY; ANTIGEN; AZATHIOPRINE; COLLAGEN TYPE 10; COLLAGEN XIII; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLAVOPROTEIN; GLUCOCORTICOID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MITOCHONDRIAL ENZYME; PREDNISOLONE; PROTEIN G; RADIOACTIVE IODINE; SOMATOSTATIN DERIVATIVE; SUCCINATE DEHYDROGENASE; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CROSS REACTION; DECOMPRESSION SURGERY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; ENDOCRINE OPHTHALMOPATHY; EYE DISEASE; EYE SURGERY; GLUCOSE INTOLERANCE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

CLINICAL TRIALS; GRAVES DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OCULOMOTOR MUSCLES; OPHTHALMOLOGIC SURGICAL PROCEDURES; ORBIT; PRACTICE GUIDELINES;

EID: 4444361605     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00662.x     Document Type: Review

References (64)

1. Bahn RS. Clinical review 157. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003; 88: 1939-46.
2. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168-99.
3. Yamada M, Li AW, Wall JR. Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management. Crit Rev Clin Laboratory Sci 2000; 37: 523-49.
4. Solovyeva TP. Endocrine ophthalmopathies: problems of rational classification. Orbit 1989; 8: 193-8.
5. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001; 55: 283-303.
6. Asman P. Ophthalmological evaluation in thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 2003; 81: 437-48.
7. Salvi M, Scalise D, Stolarski C, Arthurs B, Lindley S, Kennerdell J et al. Upper eyelid retraction in the absence of other evidence for progressive ophthalmopathy is associated with eye muscle autoantibodies. Clin Immunol Immunopathol 1995; 74: 44-50.
8. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003; 24: 802-35.
9. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet 1991; 338: 25-8.
10. Wiersinga WM, Prummel MF. Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 2002; 13: 280-7.
11. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-8.
12. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326: 1733-8.
13. Gorman CA, Offord KP. Therapy for hyperthyroidism and Graves' ophthalmopathy. N Engl J Med 1998; 338: 1546-7.
14. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81: 2986-93.
15. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-48.
16. Walsh JP. Management of Graves' disease in Australia. Aust N Z J Medical 2000; 30: 559-66.
17. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349-52.
18. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002; 12: 855-60.
19. Villadolid MC, Yokoyama N, Izumi M, Nishikawa T, Kimura H, Ashizawa K et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995; 80: 2830-3.
20. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995; 120: 511-7.
21. Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid 2002; 12: 839-47.
22. Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993; 38: 367-72.
23. Tellez M, Cooper J, Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992; 36: 291-4.
24. Joffe B, Gunji K, Panz V, Zouvanis M, Swanson J, Ackrell BA et al. Thyroid-associated ophthalmopathy in black South African patients with Graves' disease: relationship to antiflavoprotein antibodies. Thyroid 1998; 8: 1023-7.
25. Kahaly GJ, Hardt J, Petrak F, Egle UT. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 2002; 12: 237-9.
26. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42: 45-50.
27. Weetman AP. Thyroid-associated ophthalmopathy. Autoimmunity 1992; 12: 215-22.
28. Small RG. Enlargement of levator palpebrae superioris muscle fibers in Graves' ophthalmopathy. Ophthalmology 1989; 96: 424-30.
29. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000; 52: 267-71.
30. Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999; 84: 2557-62.
31. Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 1993; 3: 297-300.
32. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves' orbital adipose/ connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998-1002.
33. Bell A, Gagnon A, Grunder L, Parikh SJ, Smith TJ, Sorisky A. Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol 2000; 279: C335-40.
34. Gunji K, De Bellis A, Li AW, Yamada M, Kubota S, Ackrell B et al. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1641-7.
35. Kaspar M, De Archibald CBA, Li AW, Yamada M, Chang CH et al. Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy. Thyroid 2002; 12: 187-91.
36. Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B et al. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1999; 84: 1255-62.
37. Gunji K, Skolnick C, Bednarczuk T, Benes S, Ackrell BA, Cochran B et al. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. Clin Immunol Immunopathol 1998; 87: 276-81.
38. Atabay C, Tyutyunikov A, Scalise D, Stolarski C, Hayes MB, Kennerdell JS et al. Serum antibodies reactive with eye muscle membrane antigens are detected in patients with nonspecific orbital inflammation. Ophthalmology 1995; 102: 145-53.
39. Kubota S, Gunji K, Ackrell BA, Cochran B, Stolarski C, Wengrowicz S et al. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 443-7.
40. Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Wall JR. A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. Autoimmunity 1999; 29: 1-9.
41. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci U S A 2001; 98: 12062-7.
42. Gunji K, Kubota S, Swanson J, Kiljanski J, Bednarczuk T, Wengrowicz S et al. Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens. Thyroid 1998; 8: 553-6.
43. Dong Q, Ludgate M, Vassart G. Cloning and sequencing of a novel 64-kDa autoantigen recognized by patients with autoimmune thyroid disease. J Clin Endocrinol Metab 1991; 72: 1375-81.
44. Kromminga A, Hagel C, Arndt R, Schuppert F. Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: a possible autoantigenic link in Graves' patients. J Clin Endocrinol Metab 1998; 83: 2817-23.
45. Busuttil BE, Frauman AG. Extrathyroidal manifestations of Graves' disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues. J Clin Endocrinol Metab 2001; 86: 2315-9.
46. Wall JR, Bernard N, Boucher A, Salvi M, Zhang ZG, Kennerdell J et al. Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves' hyperthyroidism and Hashimoto's thyroiditis. Clin Immunol Immunopathol 1993; 68: 1-8.
47. Barsouk A, Wengrowicz S, Scalise D, Stolarski C, Nebes V, Sato M et al. New assays for the measurement of serum antibodies reactive with eye muscle membrane antigens confirm their significance in thyroid-associated ophthalmopathy. Thyroid 1995; 5: 195-200.
48. Hiromatsu Y, Cadarso L, Salvi M, Wall JR. Significance of cytotoxic eye muscle antibodies in patients with thyroid-associated ophthalmopathy. Autoimmunity 1990; 5: 205-13.
49. Yamada M, Li AW, West KA, Chang CH, Wall JR. Experimental model for ophthalmopathy in BALB/c and outbred (CD-1) mice genetically immunized with G2s and the thyrotropin receptor. Autoimmunity 2002; 35: 403-13.
50. Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1998; 49: 21-8.
51. Prummel MF, Wiersinga WM. Immunomodulatory treatment of Graves' ophthalmopathy. Thyroid 1998; 8: 545-8.
52. Kahaly G, Pitz S, Muller-Forell W, Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996; 106: 197-202.
53. Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989; 321: 1353-9.
54. Wall JR, Strakosch CR, Fang SL, Ingbar SH, Braverman LE. Thyroid binding antibodies and other immunological abnormalities in patients with Graves' ophthalmopathy: effect of treatment with cyclophosphamide. Clin Endocrinol (Oxf) 1979; 10: 79-91.
55. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001; 144: 311-8.
56. De Rosa G, Menichella G, Della S, Rossi PL, Testa A, Pierelli L et al. Plasma exchange in Graves' ophthalmopathy. Prog Clin Biol Res 1990; 337: 321-5.
57. Perros P, Weightman DR, Crombie AL, Kendall-Taylor P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh) 1990; 122: 8-12.
58. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001; 108: 1523-34.
59. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56: 1139-44.
60. Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000; 355: 1505-9.
61. Krassas GE. Octreoscan in thyroid-associated ophthalmopathy. Thyroid 2002; 12: 229-31.
62. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 2003; 148: 1-9.
63. Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A, Sinisi AA. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 2000; 25: 63-71.
64. De Bellis A, Bizzaro A, Conte M, Coronella C, Solimeno S, Perrino S et al. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in occular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy. Clin Endocrinol (Oxf) 2003; 59: 388-95.